Evidence map›Paper›PMID 35729105›Full record

ArticleOncogenesis2022

MYCN induces cell-specific tumorigenic growth in RB1-proficient human retinal organoid and chicken retina models of retinoblastoma.

Maria K E Blixt, Minas Hellsand, Dardan Konjusha, Hanzhao Zhang, Sonya Stenfelt, Mikael Åkesson, Nima Rafati, Tatsiana Tararuk, Gustav Stålhammar, Charlotta All-Eriksson and 2 more

Open access · goldAbstract read
In one paragraph

Article in Oncogenesis, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
3.7field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Mutation spectrum of retinoblastoma patients in Vietnam.Molecular genetics & genomic medicine · 2023
    Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Maria K E Blixt *Department of Immunology, Genetics, and Pathology, Uppsala University, Uppsala, Sweden.
Minas Hellsand *Department of Immunology, Genetics, and Pathology, Uppsala University, Uppsala, Sweden.ORCID http://orcid.org/0000-0002-1459-0377
Dardan Konjusha *Department of Immunology, Genetics, and Pathology, Uppsala University, Uppsala, Sweden.ORCID http://orcid.org/0000-0002-6959-8376
Hanzhao ZhangDepartment of Immunology, Genetics, and Pathology, Uppsala University, Uppsala, Sweden.
Sonya StenfeltDepartment of Immunology, Genetics, and Pathology, Uppsala University, Uppsala, Sweden.
Mikael ÅkessonDepartment of Immunology, Genetics, and Pathology, Uppsala University, Uppsala, Sweden.
Nima RafatiNational Bioinformatics Infrastructure Sweden, Uppsala University, SciLifeLab, Department of Medical Biochemistry and Microbiology, Uppsala, Sweden.ORCID http://orcid.org/0000-0002-3687-9745
Tatsiana TararukDepartment of Immunology, Genetics, and Pathology, Uppsala University, Uppsala, Sweden.
Gustav StålhammarSt. Erik Eye Hospital, Department of Clinical Neuroscience, Karolinska Institute, Stockholm, Sweden.
Charlotta All-ErikssonSt. Erik Eye Hospital, Department of Clinical Neuroscience, Karolinska Institute, Stockholm, Sweden.
Henrik RingDepartment of Immunology, Genetics, and Pathology, Uppsala University, Uppsala, Sweden.
Finn HallböökDepartment of Immunology, Genetics, and Pathology, Uppsala University, Uppsala, Sweden. finn.hallbook@igp.uu.se.ORCID http://orcid.org/0000-0001-7552-187X
Uppsala University · SEKarolinska Institutet · SE

Funding

Barncancerfonden (Swedish Childhood Cancer Foundation) PR2019-0068, PR2017-0105Vetenskapsrådet (Swedish Research Council) 2016-01641
6 · The paper itself

Abstract

Retinoblastoma is a rare, intraocular paediatric cancer that originates in the neural retina and is most frequently caused by bi-allelic loss of RB1 gene function. Other oncogenic mutations, such as amplification and increased expression of the MYCN gene, have been found even with proficient RB1 function. In this study, we investigated whether MYCN over-expression can drive carcinogenesis independently of RB1 loss-of-function mutations. The aim was to elucidate the events that result in carcinogenesis and identify the cancer cell-of-origin. We used the chicken retina, a well-established model for studying retinal neurogenesis, and established human embryonic stem cell-derived retinal organoids as model systems. We over-expressed MYCN by electroporation of piggyBac genome-integrating expression vectors. We found that over-expression of MYCN induced tumorigenic growth with high frequency in RB1-proficient chicken retinas and human organoids. In both systems, the tumorigenic cells expressed markers for undifferentiated cone photoreceptor/horizontal cell progenitors. The over-expression resulted in metastatic retinoblastoma within 7-9 weeks in chicken. Cells expressing MYCN could be grown in vitro and, when orthotopically injected, formed tumours that infiltrated the sclera and optic nerve and expressed markers for cone progenitors. Investigation of the tumour cell phenotype determined that the potential for neoplastic growth was embryonic stage-dependent and featured a cell-specific resistance to apoptosis in the cone/horizontal cell lineage, but not in ganglion or amacrine cells. We conclude that MYCN over-expression is sufficient to drive tumorigenesis and that a cell-specific resistance to apoptosis in the cone/horizontal cell lineage mediates the cancer phenotype.

Identifiers

PMID35729105
PMCPMC9213451
OpenAlexW4283259879

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.